Pulmonary Embolism in a Woman Taking Oral Contraceptives and Valdecoxib 英文参考文献.docVIP

下载本文档

4
0
约8.76千字
约 2页
2017-05-13 发布于上海
举报
版权申诉

Pulmonary Embolism in a Woman Taking Oral Contraceptives and Valdecoxib 英文参考文献.doc

1、本文档共2页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Pulmonary Embolism in a Woman Taking Oral Contraceptives and Valdecoxib 英文参考文献

o Openaccess,freelyavailableonline PL S MEDICINE CaseReport PulmonaryEmbolisminaWomanTakingOral ContraceptivesandValdecoxib Elizabeth J.Westgate, Garret A.FitzGerald* CasereportfromtheInstituteforTranslationalMedicineandTherapeutics,UniversityofPennsylvania,Philadelphia,Pennsylvania,UnitedStatesofAmerica PRESENTATIONofCASE CompetingInterests:Theauthors havedeclaredthatnocompeting interestsexist. Risk factors for spontaneous thrombosis include oral contraceptives, genetic predis- position to a hypercoaguable state, and prolonged periods of stasis [4–6]. At least tworiskfactorspertainedtothispatient. The patient had been taking oral contra- ceptives for 3 y prior to the index event, albeit without recognized thrombotic com- plication. It is possible that despite this extended period of apparent tolerance, the embolic events were solely related to use of theoralcontraceptives[4]. The relatively small risk of venous throm- boembolism attributable to oral contracep- tive use may interact geometrically with the similarlysmallabsoluteriskofaprocoagulant mutation, such as Factor V Leiden [5]. However, documented genetic risk factors, suchasabnormalitiesinlupusanticoagulant, anti-thrombin III, proteins C and S, plasma homocysteine, anticardiolipin, b2 glycopro- tein antibody, and prothrombotic mutations inFactorVandprothrombinwereexcluded. It remains possible that the patient was genetically predisposed to thrombosis by a mutationinanundeterminedfactor. Finally,prolongedstasis,suchasthatwhich occurredduringthe6-hcartrip,mayaccount for the clinical event [6]. However, the absolute risk is small, and the patient had made this trip on multiple occasions devoid ofapparentclinicalcomplicationsduringthe prior3y. Theriskofthrombosisfromvaldecoxibhas nowbeenestablished[3,7],andthis,together with its propensity rarely to cause Stevens- Johnsonsyndromewithoutamitigatingben- e?tovertraditionalnonsteroidalanti-in?am- matorydrugs,hasledtoitswithdrawalfrom the market. The car